Lyell Immunopharma, Inc. (LYEL) vs Anbio Biotechnology Class A Ordinary Shares (NNNN)
A side-by-side comparison of Lyell Immunopharma, Inc. and Anbio Biotechnology Class A Ordinary Shares across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
LYEL
Lyell Immunopharma, Inc.
$8.77HealthcareDelayed quote: Oct 6, 2026, 11:05 AM EDT
NNNN
Anbio Biotechnology Class A Ordinary Shares
$4.95HealthcareDelayed quote: Oct 6, 2026, 11:04 AM EDT
Total return — LYEL vs NNNN
growth of $100 · dividends reinvested · last 2yLYEL -26.7% (-14.4%/yr)NNNN -16.3% (-8.5%/yr)NNNN compounded faster over this window
LYEL NNNN
LYEL vs NNNN: by the numbers
- •NNNN is the larger company ($217M vs $215M market cap).
- •NNNN is profitable (74.06% net margin) while LYEL runs a net loss (-920285.19%).
Metrics side by side
Valuation
| Metric | LYEL | NNNN |
|---|---|---|
| P/S ratio | 7959.38 | N/A |
| P/B ratio | 0.92 | 7.20 |
Profitability
| Metric | LYEL | NNNN |
|---|---|---|
| Gross margin | -31952.78% | 87.24% |
| Operating margin | -566038.89% | 66.70% |
| Net margin | -920285.19% | 74.06% |
| ROE | -106.27% | 21.24% |
| ROIC | -70.80% | 19.13% |
Growth (annualized)
| Metric | LYEL | NNNN |
|---|---|---|
| Revenue CAGR (5Y) | -68.32% | N/A |
| Total return CAGR (5Y) | -48.18% | N/A |
Frequently asked
- Is LYEL or NNNN more profitable?
- NNNN runs the higher net margin — LYEL at -920285.19% versus NNNN at 74.06%.
Go deeper
Dig into the metrics
Lyell Immunopharma ROEAnbio Biotechnology Class A Ordinary Shares ROELyell Immunopharma operating marginAnbio Biotechnology Class A Ordinary Shares operating marginLyell Immunopharma revenue growthAnbio Biotechnology Class A Ordinary Shares revenue growthLyell Immunopharma free cash flowAnbio Biotechnology Class A Ordinary Shares free cash flow
Lyell Immunopharma & Anbio Biotechnology Class A Ordinary Shares appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.